Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC raised its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 36.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,144 shares of the biotechnology company’s stock after purchasing an additional 7,484 shares during the quarter. Natixis Advisors LLC’s holdings in Corcept Therapeutics were worth $1,303,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in CORT. Empowered Funds LLC purchased a new stake in shares of Corcept Therapeutics in the 3rd quarter worth about $1,784,000. Royce & Associates LP lifted its holdings in shares of Corcept Therapeutics by 3.7% in the third quarter. Royce & Associates LP now owns 363,272 shares of the biotechnology company’s stock valued at $16,812,000 after purchasing an additional 13,000 shares in the last quarter. Black Diamond Financial LLC purchased a new position in shares of Corcept Therapeutics during the 3rd quarter worth approximately $231,000. CIBC Asset Management Inc acquired a new position in shares of Corcept Therapeutics during the 3rd quarter worth approximately $241,000. Finally, Intellectus Partners LLC acquired a new position in shares of Corcept Therapeutics during the 3rd quarter worth approximately $2,539,000. 93.61% of the stock is owned by hedge funds and other institutional investors.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT opened at $58.58 on Wednesday. Corcept Therapeutics Incorporated has a 12-month low of $20.84 and a 12-month high of $61.66. The company has a market cap of $6.14 billion, a PE ratio of 46.49 and a beta of 0.45. The stock has a 50 day simple moving average of $48.82 and a 200-day simple moving average of $38.29. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. During the same period in the prior year, the firm posted $0.28 earnings per share. The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. On average, equities research analysts forecast that Corcept Therapeutics Incorporated will post 1.35 EPS for the current year.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.88, for a total transaction of $131,736.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joseph Douglas Lyon sold 1,411 shares of the company’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $56.72, for a total value of $80,031.92. Following the completion of the transaction, the insider now directly owns 8,494 shares in the company, valued at approximately $481,779.68. The trade was a 14.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,611 shares of company stock valued at $1,563,548 over the last ninety days. Corporate insiders own 20.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on CORT shares. Piper Sandler lifted their price target on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, September 18th. Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Corcept Therapeutics in a report on Thursday, October 31st. Canaccord Genuity Group reiterated a “buy” rating and issued a $38.00 target price on shares of Corcept Therapeutics in a research note on Tuesday, July 30th. Finally, StockNews.com cut Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $65.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.